- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04913272
Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV (CKD)
A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Kidney diseases are a global public health problem that affects over 200 million people worldwide. It is estimated that about 30 million adults in the United States have Chronic Kidney Disease (CKD) and most are undiagnosed. In addition, CKD represents the ninth leading cause of death in the United States. Kidney diseases also represent great socio-economical cost worldwide. In the United States, treating Medicare beneficiaries with CKD costed over $79 billion, and treating people with End Stage Kidney Disease (ESKD) costed an additional $35 billion in 2016. To date, there is no cure for CKD.
The most important CKD risk factors in adults include diabetes and high blood pressure. Other risk factors include heart disease, obesity, a family history of CKD, past damage to the kidneys, and old age. Having CKD increases the chances of also having heart disease and stroke.
CKD is a condition characterized by a gradual loss of kidney function over time. Depending on the kidney function measured with glomerular filtration rate (GFR) CKD can be classified into several stages (I, II, III, IV and V). CKD Stage V, also known as End Stage Kidney Disease (ESKD), is a very advanced stage of kidney disease where the kidneys have lost nearly all ability to do their job effectively, and eventually dialysis or a kidney transplant is needed to live. Treatment may slow the decline in kidney function and failure. However, not everyone with CKD develops ESKD, and in some cases ESKD develops even with treatment.
CKD is accompanied by altered pathogenic gut bacteria, inflammation, and accumulation of uremic toxins in the blood. These blood uremic toxins can diffuse passively into the bowel. Scientific research has shown that probiotic bacteria could metabolize various uremic toxins such as urea, uric acid, and creatinine. In addition, by supplementing the gut microbiome with probiotic bacteria, it is possible to metabolize the nitrogenous waste products and other toxins which diffuse into the gut, and thus lower levels of inflammation and blood uremic toxins.
KT-301 (formerly US-APR2020) is a live biotherapeutic (LBT) intended to restore the gut microbiome to improve the removal of uremic toxins in the bowel in CKD patients. The aim of this Phase 2 study is to evaluate the safety and efficacy of the KT-301 in the management of patients with CKD Stage IV.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mukesh Kumar, PhD
- Phone Number: 2407504893
- Email: mkumar@fdamap.com
Study Locations
-
-
Maryland
-
Silver Spring, Maryland, United States, 20904
- Recruiting
- Jadedstone Clinical Research
-
Contact:
- Mukesh Kumar
- Phone Number: 240-750-4893
- Email: mkumar@fdamap.com
-
-
Michigan
-
Saginaw, Michigan, United States, 48604
- Recruiting
- Kidney Michigan
-
Contact:
- Mukesh Kumar
- Phone Number: 240-750-4893
- Email: mkumar@fdamap.com
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Recruiting
- South Carolina Clinical Research
-
Contact:
- Mukesh Kumar
- Phone Number: 240-750-4893
- Email: mkumar@fdamap.com
-
-
Texas
-
Houston, Texas, United States, 77058
- Recruiting
- Almeda Medical Clinic
-
Contact:
- Mukesh Kumar
- Phone Number: 240-750-4893
- Email: mkumar@fdamap.com
-
-
Virginia
-
Woodbridge, Virginia, United States, 22192
- Recruiting
- Mendez Center for Clinical Research
-
Contact:
- Mukesh Kumar
- Phone Number: 240-750-4893
- Email: mkumar@fdamap.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults between the ages of 18-80 years
- CKD Stage IV (eGFR = 15-29 mL/min) with declining kidney function for a period > 6 months
- Serum Creatinine > 2.0 mg/dL
- Adherence to low protein diet (LPD) of 0.6-0.8 g/kg/day based on subject response and on advisory
Exclusion Criteria:
- Those on probiotic supplements in the past 3 months
- Pregnancy, breast feeding or females of child-bearing potential who are unwilling to use a reliable form of contraception.
- Immunosuppressant medications therapy specific to immune mediated renal diseases
- HIV/AIDs
- Underweight (BMI ≤ 18.5)
- Subject with an infection that requires oral antibiotic administration at the time of randomization or close to that visit.
- Those with gastrointestinal disease (irritable bowel syndrome or anal fissures or anal fistulas or perianal abscesses or perianal infections or diverticular diseases or colitis or colon polyps) at the time of screening and randomization, or within 6 months prior to the randomization visit (Visit 2)
- Those with internal prosthesis including orthopedics, neurosurgery, heart valves, vascular stents ˂ 2 years post -surgery procedure. Those with Prosthesis > 2 years should not be excluded.
- Those with biological/tissue grafts or prosthesis or implant
- Those on anticoagulant medicines, including Vit K antagonists (e.g., warfarin, coumadin) or the new class of oral anti-coagulants approved by FDA in the last 10 years
- Those on peritoneal dialysis
- Those with acute kidney injury
- Those with mental conditions or medically debilitating disease/disorder other than CKD, which, in the judgment of the investigator, would interfere with or serve as a contraindication to adherence to the study protocol or affect the ability to give informed consent or affect overall prognosis of the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: KT-301 (formerly US-APR2020)
Patients in this group will be administered KT-301 (formerly US-APR2020) orally at 2 capsules per day for six months.
The frequency will be one capsule in the morning and one capsule in the evening, after meals, (for a total daily dose of 90 Billion CFUs).
|
US-APR2020 capsules 45 billion CFUs of the LBT.
|
PLACEBO_COMPARATOR: Placebo
Patients in this group will be administered placebo orally at 2 capsules per day for six months.
The frequency will be one capsule in the morning and one capsule in the evening, after meals.
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate incidences of Treatment-Emergent Adverse Events following KT-301 (formerly US-APR2020) administration in patients with Chronic Kidney disease (CKD) Stage IV as a measure of safety.
Time Frame: six months
|
Presence of adverse events in less than 10% of the study population, as a measure of safety
|
six months
|
Evaluate the change of eGFR as per NKF-USFDA guidelines following KT-301 (formerly US-APR2020) administration in patients with Chronic Kidney disease (CKD) Stage IV as a measure of clinical efficacy.
Time Frame: six months
|
Arresting the change of Estimated glomerular filtration rate (eGFR) as per National Kidney Foundation- US Food and Drug Administration (NKF-USFDA )guidelines in the group treated with KT-301 (formerly US-APR2020) as compared to the placebo, as a measure of efficacy.
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate changes in basic blood uremic metabolic markers
Time Frame: six months
|
Change in any of the basic blood uremic metabolic markers in the group treated with KT-301 (formerly US-APR2020) as compared to the placebo:
|
six months
|
Evaluate changes in complete blood count and hematology parameters
Time Frame: six months
|
Change in any of the complete blood count (CBC) and hematology parameters in the group treated with KT-301 (formerly US-APR2020) as compared to the placebo:
|
six months
|
Evaluate changes in C-Reactive Protein (CRP) levels
Time Frame: six months
|
Change in C-Reactive Protein (CRP) levels in the group treated with KT-301 (formerly US-APR2020) as compared to the placebo
|
six months
|
Evaluate change in quality of life (QOL)- SF36 QOL questionnaire
Time Frame: six months
|
six months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- US-APR2020-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease stage4
-
Erasmus Medical CenterCompletedAC/DC Study: Acidification Test in Patients With Chronic Kidney Disease and Healthy Controls (AC/DC)Chronic Kidney Disease stage4Netherlands
-
CalydialHospices Civils de LyonUnknownKidney Diseases | Chronic Kidney Disease stage4France
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
JemincareShanghai 6th People's HospitalUnknownEfficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to GlomerulonephritisGlomerulonephritis | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3B
-
Centre Hospitalier Universitaire de BesanconCompletedChronic Kidney Disease stage4France
-
Stanford UniversityEmory University; Santa Clara Valley Medical CenterCompletedPhysical Activity | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage VUnited States
-
Washington D.C. Veterans Affairs Medical CenterUnknownChronic Kidney Disease stage4 | Chronic Kidney Disease stage3United States
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States